CORZR (CORZR)

Insider Trading Filed: 2026-04-15

Todd DuChene, the Chief Legal and Administrative Officer, sold a total of 10,000 shares of Core Scientific, Inc. on April 13, 2026 at weighted average prices of $18.61 and $18.99.
The transactions were made pursuant to a Rule 10b5-1 trading plan adopted by DuChene on December 5, 2025, indicating a planned and systematic approach to the share sales.
After the reported transactions, DuChene still holds a significant stake of 2,027,089 shares in the company, suggesting he maintains a substantial ownership position.

Current Report Filed: 2026-03-06

Core Scientific, Inc. has entered into a $500 million senior secured loan facility, which can be increased by an additional $500 million through an accordion feature. The proceeds will be used for general corporate purposes related to data center development.
The loan facility matures in 364 days and bears interest at a rate equal to term SOFR plus an applicable margin of 2.50% per annum.
The company's obligations under the loan facility are guaranteed by its wholly-owned material domestic subsidiaries and secured by a first-priority lien on substantially all of its assets.

Current Report Filed: 2026-02-18

Core Scientific entered into a cooperation agreement with Two Seas Capital, which includes the appointment of three new independent directors and limits on board size changes.
Jordan Levy, the current Chairman of the Board, will not stand for re-election at the 2026 Annual Meeting.
The company issued two classes of warrants with exercise prices of $6.81 and $0.01 per share.

Insider Trading Filed: 2026-02-06

The reporting person, Eric Stanton Weiss, has been granted 18,575 restricted stock units (RSUs) by Core Scientific, Inc. The RSUs will vest in full on February 3, 2027, provided that Weiss continues to serve as a non-employee director of the company.
Weiss currently holds 245,262 shares of Core Scientific's common stock, indicating his continued involvement and commitment to the company as a director.
The RSU grant suggests that Core Scientific is providing equity-based incentives to its non-employee directors, which could align their interests with those of shareholders.

Insider Trading Filed: 2026-02-06

Yadin Rozov, a director of Core Scientific, Inc., acquired 18,575 restricted stock units (RSUs) on February 4, 2026, which will vest fully on February 3, 2027 provided he continues to serve as a non-employee director.
This acquisition of RSUs by a director suggests their alignment with the company's long-term performance and commitment to the organization.
The vesting schedule of the RSUs, which requires continued service as a director, aligns the interests of the director with the shareholders and incentivizes their long-term involvement in the company.

Insider Trading Filed: 2026-02-06

The filing indicates that Elizabeth Crain, a director of Core Scientific, Inc./tx, has been granted 18,575 restricted stock units (RSUs) on February 4, 2026, which will vest in full on February 3, 2027, provided that she continues to serve as a non-employee director.
The acquisition of these RSUs suggests that Crain has a direct ownership stake in the company, aligning her interests with those of other shareholders.
The timing of the RSU grant, close to the company's fiscal year-end, may indicate that it is part of Crain's regular director compensation package.

Insider Trading Filed: 2026-02-06

Jordan Levy, a director of Core Scientific, Inc./tx, has been granted 18,575 restricted stock units (RSUs) that will fully vest on February 3, 2027, provided he continues to serve as a non-employee director.
The RSU grant represents an increase in Levy's beneficial ownership of Core Scientific's common stock, which now stands at 325,462 shares.
Insider buying and vesting of equity awards can be seen as a positive signal, indicating the director's confidence in the company's long-term prospects.

Insider Trading Filed: 2026-02-06

The reporting person, Jeffrey David Booth, has received a grant of 18,575 restricted stock units (RSUs) from Core Scientific, Inc., which will vest in full on February 3, 2027, provided he continues to serve as a non-employee director.
This RSU grant indicates that the company is compensating its non-employee directors, which is a common practice to align their interests with those of shareholders.
The reporting person's total beneficial ownership of Core Scientific's common stock has increased to 214,262 shares following this transaction.

Insider Trading Filed: 2026-01-26

The CEO Adam Taylor Sullivan has sold a significant portion (274,404 shares) of his common stock holdings in Core Scientific, Inc. This may indicate a potential shift in his confidence or outlook for the company.
The timing of the stock sale, on January 23, 2026, suggests the CEO may have had access to material non-public information that influenced his decision to dispose of these shares.
The sale represents approximately 6.2% of the CEO's total beneficial ownership in the company, which could be viewed as a substantial reduction in his direct economic stake and alignment with shareholders.

Insider Trading Filed: 2026-01-05

Todd DuChene, the Chief Legal and Administrative Officer, acquired an additional 55,758 shares of Core Scientific, Inc. common stock through the vesting of performance-based restricted stock units.
DuChene also disposed of 139,873 shares to cover tax withholding obligations, indicating he continues to hold a sizable position of over 1.9 million shares in the company.
The reported transactions suggest ongoing executive confidence and alignment with shareholder interests, as the officer maintains a significant equity stake in Core Scientific.

Insider Trading Filed: 2026-01-05

Insider Adam Taylor Sullivan, CEO of Core Scientific, acquired an additional 159,308 shares of common stock through the vesting of performance-based restricted stock units, increasing his total beneficial ownership to 4.5 million shares.
Sullivan also sold 117,540 shares to cover tax withholding obligations related to the vesting of the restricted stock units, suggesting continued confidence in the company's long-term prospects.
The acquisition of shares through the vesting of performance-based units aligns Sullivan's interests with those of shareholders and indicates his commitment to Core Scientific's success.

Important Information